Advice
following a full submission:
remimazolam (Byfavo®) is not recommended for use within NHSScotland.
Indication under review: in adults for procedural sedation.
In three randomised, multicentre, phase III studies, remimazolam treatment resulted in a significantly higher rate of procedure success in patients undergoing colonoscopy or bronchoscopy when compared with placebo.
The submitting company’s justification of the treatment’s cost in relation to its health benefits was not sufficient and in addition the company did not present a sufficiently robust economic analysis to gain acceptance by SMC.
Medicine details
- Medicine name:
- remimazolam (Byfavo)
- SMC ID:
- SMC2454
- Indication:
Treatment in adults for procedural sedation.
- Pharmaceutical company
- Paion UK Limited
- BNF chapter
- Anaesthesia
- Submission type
- Full
- Status
- Not recommended
- Date advice published
- 08 August 2022